Miragen Acquires microRNA Target Rights from T2cure

According to the company, miR-92 is "a key regulator of neo-angiogenesis as part of ischemic disease, which may be relevant to peripheral arterial disease and other cardiovascular disorders."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories